Forefront Analytics, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Forefront Analytics, LLC

$206 Million
Q1 2024

A detailed history of Forefront Analytics, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Forefront Analytics, LLC holds 344 shares of REGN stock, worth $359,363. This represents 0.16% of its overall portfolio holdings.

Number of Shares

344

Previous 319 7.84%

Holding current value

$359,363

Previous $280,000 18.21%

% of portfolio

0.16%

Previous 0.14%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $22,567 - $24,833	25 Added 7.84%	344 $331,000
Q4 2023 Feb 13, 2024	BUY	$775.18 - $881.7 $20,154 - $22,924	26 Added 8.87%	319 $280,000
Q3 2023 Nov 07, 2023	SELL	$692.45 - $844.37 $33,237 - $40,529	-48 Reduced 14.08%	293 $241,000
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $11,200 - $13,285	-16 Reduced 4.48%	341 $245,000
Q1 2023 May 11, 2023	BUY	$680.49 - $826.97 $34,024 - $41,348	50 Added 16.29%	357 $293,000

Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $5,647 - $6,131	-8 Reduced 2.54%	307 $221,000
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $180,800 - $228,160	315 New	315 $216,000
Q2 2022 Aug 10, 2022	SELL	$548.35 - $738.84 $282,400 - $380,502	-515 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$595.12 - $698.43 $73,199 - $85,906	123 Added 31.38%	515 $353,000
Q4 2021 Feb 11, 2022	BUY	$543.48 - $670.97 $5,434 - $6,709	10 Added 2.62%	392 $249,000
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $22,961 - $27,238	-40 Reduced 9.48%	382 $233,000
Q2 2021 Aug 10, 2021	SELL	$472.8 - $558.54 $39,242 - $46,358	-83 Reduced 16.44%	422 $235,000
Q1 2021 May 13, 2021	BUY	$446.73 - $548.2 $225,598 - $276,841	505 New	505 $238,000

Others Institutions Holding REGN

# of Institutions

1,426

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Forefront Analytics, LLC with notifications on news.

Account

Forefront Analytics, LLC Regeneron Pharmaceuticals, Inc. Transaction History